JMP Securities Reiterates Market Outperform on Blueprint Medicines, Maintains $114 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Reni Benjamin has reiterated a 'Market Outperform' rating on Blueprint Medicines (NASDAQ:BPMC) and maintained a price target of $114.
January 16, 2024 | 2:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Blueprint Medicines has been given a 'Market Outperform' rating by JMP Securities with a price target of $114, indicating a positive outlook for the stock.
The reiteration of a 'Market Outperform' rating and the maintenance of a $114 price target by a reputable analyst like Reni Benjamin could instill confidence in investors and positively influence Blueprint Medicines' stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100